- Home
- DRMA vs AMZE Comparison
DRMA vs AMZE Comparison
Compare DRMA & AMZE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- AMZE
- Stock Information
- Founded
- DRMA 2014
- AMZE 2019
- Country
- DRMA United States
- AMZE United States
- Employees
- DRMA N/A
- AMZE N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- AMZE Beverages (Production/Distribution)
- Sector
- DRMA Health Care
- AMZE Consumer Staples
- Exchange
- DRMA Nasdaq
- AMZE Nasdaq
- Market Cap
- DRMA 4.5M
- AMZE 5.2M
- IPO Year
- DRMA 2021
- AMZE 2021
- Fundamental
- Price
- DRMA $0.71
- AMZE $9.80
- Analyst Decision
- DRMA Strong Buy
- AMZE
- Analyst Count
- DRMA 1
- AMZE 0
- Target Price
- DRMA $3.00
- AMZE N/A
- AVG Volume (30 Days)
- DRMA 118.5K
- AMZE 100.8K
- Earning Date
- DRMA 08-06-2025
- AMZE 08-13-2025
- Dividend Yield
- DRMA N/A
- AMZE N/A
- EPS Growth
- DRMA N/A
- AMZE N/A
- EPS
- DRMA N/A
- AMZE N/A
- Revenue
- DRMA N/A
- AMZE $254,711.00
- Revenue This Year
- DRMA N/A
- AMZE N/A
- Revenue Next Year
- DRMA N/A
- AMZE N/A
- P/E Ratio
- DRMA N/A
- AMZE N/A
- Revenue Growth
- DRMA N/A
- AMZE N/A
- 52 Week Low
- DRMA $0.57
- AMZE $5.78
- 52 Week High
- DRMA $5.00
- AMZE $28.72
- Technical
- Relative Strength Index (RSI)
- DRMA 53.74
- AMZE N/A
- Support Level
- DRMA $0.61
- AMZE N/A
- Resistance Level
- DRMA $0.74
- AMZE N/A
- Average True Range (ATR)
- DRMA 0.06
- AMZE 0.00
- MACD
- DRMA 0.01
- AMZE 0.00
- Stochastic Oscillator
- DRMA 67.43
- AMZE 0.00
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
About AMZE Amaze Holdings Inc. Common Stock
Amaze Holdings Inc is engaged in producer of low carb, low calorie, premium wines in the United States. The company offers bold, crisp, and creamy wines that embody health, warmth, and a deeper connection to wellness and an active lifestyle. The company currently sell seven proprietary varietals: Cabernet Sauvignon, Pinot Noir, Chardonnay, Sauvignon Blanc, Rose, Sparkling Rose, and a limited Reserve Napa Cabernet Sauvignon.